Francine Behar-Cohen discusses the treatment needs in CNV including effective anti-angiogenic drugs to inhibit the growth and survival of the neovessels and effective control of the scarring process. The introduction of OCT-A has proven useful in the identification of CNV but the real challenge is understanding when and when not to treat CNV, and which treatment approach to use. Looking to the future, whilst combination treatment of anti-VEGF therapies with corticosteroids steroids has not shown to effective through clinical trial but other drug combinations should be explored.
Keywords: CNV, anti-VEGF, anti-angiogenic, scarring, diagnosis, OCT-A, optical coherence tomography angiography, inflammation, AMD, corticosteroids, efficacy, future research.Filmed by Touch Medical Media. No external funding was involved in the production of this video.
Share this Video
Related Videos In Retina/Vitreous
J Fernando Arevalo, AAO 2020 – Intravitreal Anti-VEGF Injections for Exudative Retinal Arterial Macroaneurysms
It was a pleasure to catch up with our valued Editorial Board member, J Fernando Arevalo (Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA), who gave his insights on his topic at the retina subspecialty day at AAO 2020, intravitreal anti-VEGF injections for exudative retinal arterial macroaneurysms. Questions Could you give […]
Tommaso Rossi, EURETINA 2020 – Novel Instrument for Internal Limiting Membrane
We were delighted to catch up with Prof. Tommaso Rossi, who talked us through his presentation at EURETINA 2020 concerning a novel instrument for internal limiting membrane, amniotic and retinal flap manipulation. Questions What is the rationale for the use of amniotic membrane grafts in vitreoretinal surgery, and in what ophthalmic indications are they used? […]
Peter Stalmans, EURETINA 2020 – End-stage Retinitis Pigmentosa Patients Implanted with 3D–neural Interface Retinal Prosthesis
Prof. Peter Stalmans (University Hospitals, Leuven, Belgium) talked us through his presentation at EURETINA on first reported clinical results from end-stage retinitis pigmentosa patients implanted with an innovative 3D neural interface retinal prosthesis. Questions Could you give us an overview of advances in retinal prosthesis approaches in the treatment of advanced retinitis pigmentosa […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!